Rebyota (fecal microbiota or fecal microbiota live – jslm) is used to prevent Clostridioides difficile (C. diff) infection from coming back after the initial infection has already been treated. It's a microbiome-based treatment made up of a mix of important microbes that help maintain gut health. Rebyota (fecal microbiota) is a solution that's given rectally as a one-time dose at the provider's office. Some side effects of this medication include stomach pain and bloating.
In a healthy gut, there's a mixture of different bacteria (as well as other microbes) that are important for your well-being. When this mixture is out of balance, you're at risk for serious gut infections, like C. diff infections.
Rebyota (fecal microbiota) is made up of different gut bacteria. It's thought to work by restoring the right balance of bacteria needed for a heathy gut.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Rebyota (fecal microbiota) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Rebyota (fecal microbiota) is made with strict manufacturing standards to make sure its free from viruses or other germs that can make you sick. But because it's made from human fecal matter, there's a chance it carries a risk for infection. If you develop a fever or signs of an infection after your Rebyota (fecal microbiota) dose, contact your provider right away. Your provider will also report this to the company who makes Rebyota (fecal microbiota).
Similarly to the risk above, there's a chance your Rebyota (fecal microbiota) dose might contain a food allergen since it's made from human fecal matter. For example, if you have a serious kiwi allergy and the donor for Rebyota (fecal microbiota) recently ate a kiwi, there's a chance you could have an allergic reaction. To be safe, tell your provider about all of your allergies before your dose, and they'll likely monitor you for any potential reactions after your Rebyota (fecal microbiota) dose.
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 1 single-dose | 1 carton | $9,040.92 | $9,040.92 |
Rebyota (fecal microbiota) is given as a single dose at your provider's office, typically 1-3 days after your last dose of antibiotics for C. difficile.
The typical dose is 150 mL delivered into the rectum over a few minutes.
No, Rebyota isn't an antibiotic. It's a mixture of microbes that's given to help maintain your gut health after you've taken antibiotics to treat your C. difficile infection.
Rebyota is given rectally at the provider's office. Before the dose, your provider will first ask you to go use the restroom, so that your bladder and bowels are empty. Then, you'll lie down, either on your left side or kneeled with your rear end in the air. Your provider will insert a tube gently into your rectum (just inside the anus) and deliver your Rebyota dose over several minutes. You'll need to remain lying down for up to 15 minutes to help lessen any cramping.
No. You don't need to take a bowel prep, avoid eating, or require any anesthesia before your provider gives you Rebyota.
Each Rebyota dose is sourced from stool that's been donated by humans. Each donor and dose of Rebyota goes through strict testing and screening to make sure Rebyota is safe. But because Rebyota comes from human fecal matter, there's a possibility that it might carry a risk for infection, though the risk is low. Let your provider know right away if you feel sick or have a fever after a dose.
In a clinical study, 71% of people who took Rebyota were free from repeat C. difficile infections 2 months after treatment, compared to 58% of people who received placebo. Of those who had success with Rebyota, about 90% remained free from C. difficile infection after 6 months.